Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 2
2017 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes.
Solini A, Rossi C, Mazzanti CM, Proietti A, Koepsell H, Ferrannini E. Solini A, et al. Diabetes Obes Metab. 2017 Sep;19(9):1289-1294. doi: 10.1111/dom.12970. Epub 2017 May 22. Diabetes Obes Metab. 2017. PMID: 28419670
AIM: To quantify the expression of sodium-glucose co-transporter (SGLT)2 and SGLT1, their cognate basolateral transporters, GLUT2 and GLUT1, and the transcriptional regulator of SGLTs in renal tissue obtained from peo …
AIM: To quantify the expression of sodium-glucose co-transporter (SGLT)2 and SGLT1, …
Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R, Wei L, Yamada K, Hara T, Kuriyama C, Okuda S, Ueta K, Shiotani M, Nagamori S, Kanai Y. Ohgaki R, et al. J Pharmacol Exp Ther. 2016 Jul;358(1):94-102. doi: 10.1124/jpet.116.232025. Epub 2016 Apr 27. J Pharmacol Exp Ther. 2016. PMID: 27189972
Canagliflozin, a selective sodium/glucose cotransporter (SGLT) 2 inhibitor, suppresses the renal reabsorption of glucose and decreases blood glucose level in patients with type 2 diabetes. ...Inhibition …
Canagliflozin, a selective sodium/glucose cotransporter (SGLT) 2 inhibitor, suppresses the renal reabsorp …
Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
Chichger H, Cleasby ME, Srai SK, Unwin RJ, Debnam ES, Marks J. Chichger H, et al. Exp Physiol. 2016 Jun 1;101(6):731-42. doi: 10.1113/EP085670. Epub 2016 May 10. Exp Physiol. 2016. PMID: 27164183 Free article.
SGLT2 inhibitors are now in clinical use to reduce hyperglycaemia in type II diabetes. However, renal glucose reabsorption across the brush border membrane (BBM) is not completely understood in diabetes. ...GLUT- and SGLT-mediated gluc
SGLT2 inhibitors are now in clinical use to reduce hyperglycaemia in type II diabetes. However, renal glucose re …